Tegavivint, a downstream Wnt/β-catenin inhibitor: Dose-finding results from a phase 1/2 trial in advanced hepatocellular carcinoma (aHCC).
Year: 2026
Type: conference-abstract
Source: Journal of Clinical Oncology
Institutions: The University of Texas Southwestern Medical Center, Princess Margaret Cancer Centre, University of Chicago Medicine Comprehensive Cancer Center, University of Miami, Sylvester Comprehensive Cancer Center, The University of Texas MD Anderson Cancer Center, University of Washington, Fred Hutch Cancer Center, Levine Cancer Institute, University of Minnesota, University of Minnesota, Duluth, Iterion Therapeutics (United States), City Of Hope National Medical Center, City of Hope
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: closed
Funder: Iterion Therapeutics
OpenAlex ID: W7162561749